Abstract
Jane is a 56-year-old lady referred to liver clinic with a positive for hepatitis C virus (HCV) antibody after presenting to her GP with tiredness. She has no active medical history, takes no regular medication and denies any intravenous drug use in the past. She informs you on further questioning that she had a road traffic accident in 1980 and underwent surgery on a left femoral fracture. At this time, she was given blood products. She drinks between two and three bottles of wine per week and works as a teaching assistant. Clinical examination is remarkable for the presence of palmer erythema only. Blood testing reveals:
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(s2):30–60.
Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther. 2016;43:562–74.
Frank C, Mohamed MK, Strickland GT, Lavanchy D, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–91.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292–303.
Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, Larrey D, Cacoub P, De Ledinghen V, Bourlière M, Bernard PH. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the french early access program (anrs co20-cupic). J Hepatol. 2012;56:S4. table.
Muir, Andrew J, et al. Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? Clinical Gastroenterology and Hepatology. 13(12):2166–72.
Moreno, Christophe, et al. “Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4.” J Hepatol. 2015;62.5: 1047–55.
Messina JP, Humphreys I,Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Athwal, V., Prince, M. (2017). Chronic Hepatitis C. In: Cross, T. (eds) Liver Disease in Clinical Practice. In Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-43126-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-43126-0_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43125-3
Online ISBN: 978-3-319-43126-0
eBook Packages: MedicineMedicine (R0)